Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration
Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times
Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin
Cryoprotectant Additives, Including rHSA, Improve iNK and iT Cell Health & Viability During Cryopreservation
DMSO-Free Cryopreservation Formulation As An Alternative Cryopreservation Method For Cell-based Therapies
Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations
Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin
